SpringWorks Therapeutics Inc. (SWTX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and growing sales, though they remain unprofitable, with a net loss of $53.5 million in Q3 2024. Strengths include sustained sales growth and potential back-to-back drug approvals, but risks involve market competition and aggressive goal setting.
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.
SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?
SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock?
Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect?
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 92.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
SWTX reports mixed third-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executive Officer Bhavesh Ashar - Chief Commercial Officer Jim Cassidy - Chief Medical Officer Francis Perier - Chief Financial Officer Badreddin Edris - Chief Operating Officer Conference Call Participants Anupam Rama - JPMorgan Peter Lawson - Barclays Corinne Johnson - Goldman Sachs David Nierengarten - Wedbush Securities Alec Stranahan - Bank of America Operator Good morning. My name is Tanya, and I will be your conference operator today.
SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $1.27 per share a year ago.
SpringWorks Therapeutics Merits A Speculative Buy
Since we last visited with SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently submitted a marketing application for a second candidate. The stock has pulled back recently, even as SpringWorks has funding in place to get the company to profitability in the years ahead.
Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?
SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Predict a 61.05% Upside in SpringWorks Therapeutics (SWTX): Here's What You Should Know
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 61.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA
The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas.
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now
Here, we are discussing some reasons why investing in SpringWorks (SWTX) stock now may turn out to be a prudent move.
